Trefoil Therapeutics is a clinical-stage biotechnology company based in San Diego, CA, dedicated to restoring sight to individuals suffering from corneal diseases. They are focused on developing innovative therapies utilizing the regenerative properties of naturally occurring corneal endothelial and epithelial cells. With their lead candidate, TTHX1114, an engineered form of Fibroblast Growth Factor FGF1, Trefoil Therapeutics aims to provide first-in-class treatments for various corneal conditions affecting both the front epithelial and back endothelial surfaces of the cornea.
Generated from the website